MetLife Investment Management, LLC
Position in GALT — Galectin Therapeutics Inc
CIK 1529735
Whippany, NJ
Position in GALT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$133,980
New position
Shares Held
28,875
first reported quarter
Ownership
0.029%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#45
of 98 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026MetLife Investment Management, LLC holds $433,929,439 across 249 Biotechnology names. GALT ranks #220 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
402,605 | $31,511,893 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
90,543 | $30,312,890 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
58,072 | $28,846,104 | |
| 4 | FTRE |
Fortrea Holdings Inc.
|
1,362,169 | $23,701,740 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
89,662 | $21,946,567 | |
| 6 | IMNM |
Immunome Inc.
|
859,076 | $18,203,820 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,880 | $14,266,595 | |
| 8 | CYTK |
Cytokinetics Inc
|
140,046 | $11,930,518 |
All Filings in GALT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $133,980 | 28,875 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||